Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment.
(2019) International Journal of Pharmaceutics — Vol. 559, p. 220-227 (2019)
Files
Bastiancich2019.pdf
Open Access - Adobe PDF
- 1.25 MB
Details
- Authors
Bastiancich, Chiara 
- Abstract
- Lauroyl-gemcitabine lipid nanocapsules (GemC12-LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. Wehypothesized that GemC12-LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC12-LNC formulation was evaluated in terms of physicochemical and mechanical properties. The PTX-GemC12-LNC hydrogel stability and drug release were evaluated over time showing no significant differences compared to GemC12-LNC. The drug combination was evaluated on several GBM cell lines showing increased cytotoxic activity compared to the original formulation and synergy between PTX and GemC12. Our results suggest that GemC12-LNC hydrogel can be used as nanodelivery platform for dual drug delivery to encapsulate active agents with different mechanisms of action to achieve a better antitumor efficacy against GBM or other solid tumors.
- Affiliations
Citations
Bastiancich, C., Bozzato, E., Luyten, U., Danhierr, F., Bastiat, G., & Préat, V. (2019). Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment. International Journal of Pharmaceutics, 559, 220-227. https://doi.org/10.1016/j.ijpharm.2019.01.042 (Original work published 2019)